Please assess the completion status of the following clinical trial:

Trial Title: Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to give written informed consent.~* Histologic diagnosis of melanoma.~* Unresectable locally advanced or metastatic melanoma with at least one melanoma metastasis accessible to radiation therapy.~* Measurable disease according to immune related Response Criteria~* Required values for initial laboratory tests:~WBC \>= 2000/uL ANC \>= 1000/uL Platelets \>= 75 x 103/uL Hemoglobin \>= 8 g/dL Creatinine \<= 2,5 x ULN AST/ALT \<= 2.5 x ULN for patients without liver metastasis or \<= 5 x ULN for patients with liver metastasis Total Bilirubin \<= 1,5.x ULN, (except patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)~* No active or chronic infection with HIV, Hepatitis B, or Hepatitis C.~* ECOG Performance status of 0 or 1.~* Men and women, \>= 18 years of age.~* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimized.~Exclusion Criteria:~* Suspected or known CNS tumors including brain metastasis.~* Any other malignancy form which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix.~* Autoimmune disease: Patients with a history of inflammatory bowel disease are excluded from this study, as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], systemic lupus erythematosus, autoimmune vasculitis \[e.g., Wegener's Granulomatosis\]); motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome).~* Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of ipilimumab hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea.~* Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to 1 month before or after any dose of ipilimumab).~* A history of prior treatment with ipilimumab or prior CD137 agonist or CTLA-4 inhibitor or agonist.~* Concomitant hormonal treatment, chemotherapy or immunotherapy.~* Other investigational therapy.~* Prior radiotherapy within the same body area.~* Prior radiotherapy targeting fields containing flat bones.~* Women of childbearing potential (WOCBP), defined above~* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness.~* Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 8 weeks after ipilimumab is stopped.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- radiation therapy with Ipilimumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues